Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pre-clinical research

mTOR inhibitor suppresses tumour formation

mTOR inhibitor suppresses formation of colorectal cancer caused by the inactivation of the adenomatous polyposis coli (Apc) gene, study finds. Colorectal cancer cells pictured

Source: Nephron / Wikimedia Commons

Colorectal cancer cell proliferation was suppressed using the mTOR inhibitor rapamycin (sirolimus) in a mouse model of the disease

Inactivation of the adenomatous polyposis coli (Apc) gene strongly predisposes people to develop colorectal cancer. A new approach to cancer prevention in such individuals is described in a mouse study reported in Nature (online, 5 November 2014)[1].

Researchers, led by Owen Sansom from Cancer Research UK, studied Apc-deficient mice and found that a signalling complex called mTORC1 is vital for tumour growth. They showed that mTORC1 promotes cell proliferation by controlling cell-cycle regulators; furthermore, the mTOR inhibitor rapamycin (known as sirolimus in the UK) suppressed tumour formation in Apc-deficient mice and halted tumour growth in mice with established tumours.

The data suggest that targeting mTORC1 “using existing, clinically approved drugs, such as the rapalogs, would provide clear therapeutic benefit for patients at high risk of developing colorectal cancer”, the researchers conclude.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067095

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.